Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus

Journal of Virology

Volumn 86, Issue 17, 2012, Pages 9113-9121

  Rani, Mridula ^a   Bolles, Meagan ^d   Donaldson, Eric F ^c   Van Blarcom, Thomas ^b   Baric, Ralph ^c   Iverson, Brent ^a   Georgiou, George ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

^c IL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; SARS CORONAVIRUS NEUTRALIZING ANTIBODY 80R; SARS CORONAVIRUS NEUTRALIZING ANTIBODY RS2; SARS CORONAVIRUS NEUTRALIZING ANTIBODY RSK; SARS CORONAVIRUS NEUTRALIZING ANTIBODY SK4; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL PROTECTION; CONTROLLED STUDY; DISSOCIATION CONSTANT; IMMUNE EVASION; IN VITRO STUDY; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SARS CORONAVIRUS; VERO CELL; VIRUS MUTANT; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CELL LINE; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; SARS VIRUS; SEQUENCE ALIGNMENT; SEVERE ACUTE RESPIRATORY SYNDROME; SINGLE-CHAIN ANTIBODIES;

BACTERIA (MICROORGANISMS); SARS CORONAVIRUS;

EID: 84866153989     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00233-12     Document Type: Article

References (44)

1. Becker MM, et al. 2008. Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc. Natl. Acad. Sci. U. S. A. 105:19944-19949.
2. Cingoz, O. 2009. Motavizumab. MAbs 1:439-442.
3. Du L, et al. 2009. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7:226-236.
4. Foote J, Eisen HN. 2000. Breaking the affinity ceiling for antibodies and T cell receptors. Proc. Natl. Acad. Sci. U. S. A. 97:10679-10681.
5. Foote J, Winter G. 1992. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224:487-499.
6. Fromant M, Blanquet S, Plateau P. 1995. Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction. Anal. Biochem. 224:347-353.
7. Greenough TC, et al. 2005. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J. Infect. Dis. 191:507-514.
8. Griswold KE, et al. 2005. Evolution of highly active enzymes by homology-independent recombination. Proc. Natl. Acad. Sci. U. S. A. 102:10082-10087.
9. Harvey BR, et al. 2004. Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc. Natl. Acad. Sci. U. S. A. 101:9193-9198.
10. Hayhurst A. 2000. Improved expression characteristics of single-chain Fv fragments when fused downstream of the Escherichia coli maltose-binding protein or upstream of a single immunoglobulin-constant domain. Protein Expr. Purif. 18:1-10.
11. Hayhurst A, et al. 2003. Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis. J. Immunol. Methods 276:185-196.
12. Hwang WC, et al. 2006. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J. Biol. Chem. 281:34610-34616.
13. Li F, Li W, Farzan M, Harrison SC. 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309:1864-1868.
14. Li Y, Lipschultz CA, Mohan S, Smith-Gill SJ. 2001. Mutations of an epitope hot-spot residue alter rate limiting steps of antigen-antibody protein-protein associations. Biochemistry 40:2011-2022.
15. Liang G, et al. 2004. Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg. Infect. Dis. 10:1774-1781.
16. Marra MA, et al. 2003. The Genome sequence of the SARS-associated coronavirus. Science 300:1399-1404.
17. Maynard JA, et al. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20:597-601.
18. Nie Y, et al. 2004. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J. Infect. Dis. 190:1119-1126.
19. Roberts A, et al. 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3:e5. doi:10.1371/journal.ppat.0030005.
20. Rockx B, et al. 2008. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 82:3220-3235.
21. Rockx B, et al. 2010. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J. Infect. Dis. 201:946-955.
22. Rockx B, et al. 2007. Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J. Virol. 81:7410-7423.
23. Scheid JF, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
24. Sheahan T, et al. 2011. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J. Virol. 85:217-230.
25. Stemmer WP, Crameri A, Ha KD, Brennan TM, Heyneker HL. 1995. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene 164:49-53.
26. Sui J, et al. 2008. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog. 4:e1000197. doi:10.1371/journal.ppat.1000197.
27. Sui J, et al. 2004. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. U. S. A. 101:2536-2541.
28. Sui J, et al. 2005. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J. Virol. 79:5900-5906.
29. ter Meulen J, et al. 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 3:e237. doi:10.1371/journal.pmed.0030237.
30. Tessier DC, Thomas DY, Khouri HE, Laliberte F, Vernet T. 1991. Enhanced secretion from insect cells of a foreign protein fused to the honeybee melittin signal peptide. Gene 98:177-183.
31. Toran JL, et al. 2001. Improvement in affinity and HIV-1 neutralization by somatic mutation in the heavy chain first complementaritydetermining region of antibodies triggered by HIV-1 infection. Eur. J. Immunol. 31:128-137.
32. Traggiai E, et al. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871-875.
33. Wang Z, et al. 2011. On the mechanisms of bananin activity against severe acute respiratory syndrome coronavirus. FEBS J. 278:383-389.
34. Wong SK, Li W, Moore MJ, Choe H, Farzan M. 2004. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensinconverting enzyme 2. J. Biol. Chem. 279:3197-3201.
35. Wu H, et al. 2007. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368:652-665.
36. Wu H, et al. 2005. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350:126-144.
37. Wu K, Peng G, Wilken M, Geraghty RJ, Li F. 2012. Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus. J. Biol. Chem. 287:8904-8911.
38. Yount B, et al. 2003. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U. S. A. 100:12995-13000.
39. Zhang CY, Wei JF, He SH. 2006. Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups. BMC Microbiol. 6:88.
40. Zhang MY, et al. 2010. Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. MAbs 2:266-274.
41. Zhang MY, et al. 2004. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J. Mol. Biol. 335:209-219.
42. Zhao GP. 2007. SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. Phil. Trans. R. Soc. Lond. B Biol. Sci. 362:1063-1081.
43. Zhu Q, et al. 2011. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodiesz palivizumab and/or motavizumab. J. Infect. Dis. 203:674-682.
44. Zhu Z, et al. 2007. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 104:12123-12128.